ERBB2 and breast carcinoma: In addition, the relationship between pCR and disease-free or overall survival at patient level was heavily influenced by biomolecular subtype—being much stronger for HER-2 positive or triple negative disease than for HER-2 negative, ER+ breast cancer [2].